Therapeutic options in multiple sclerosis: Five new things

Neurology

Volumn 75, Issue 18 SUPPL.1, 2010, Pages

  Miravalle, Augusto ^a   Corboy, John R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; CLADRIBINE; FINGOLIMOD; NATALIZUMAB; PLACEBO;

ARTICLE; BRADYCARDIA; CHRONIC VEIN INSUFFICIENCY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; HEADACHE; HUMAN; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHINOPHARYNGITIS; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION;

EID: 78650168511     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181fb3676     Document Type: Article

References (35)

1. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology 2010;74(suppl 3):S24-S35.
2. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomy-elitis. Nat Med 2007;13:1228-1233.
3. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oli-godendrocyte precursor cells. Ann Neurol 2009;65:304-315.
4. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003;102:2364-2372.
5. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009;8:244-253.
6. Zhang J, Brodie C, Li Y, et al. Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J Neurol Sci 2009;15:30-38.
7. Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003;422:688-694.
8. Pluchino S, Gritti A, Blezer E, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol 2009;66:343-354.
9. Rice CM, Mallam EA, Whone AL, et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 2010;87:679-685.
10. Rodriguez M. Have we finally identified an autoimmune demyelinating disease? Ann Neurol 2009;66:572-573.
11. Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009;65:639-649.
12. Zamboni P, Menegatti E, Bartolomei I, et al. Intracranial venous haemodynamics in multiple sclerosis. Curr Neuro-vasc Res 2007;4:252-258.
13. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebro-spinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392-399.
14. Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospi-nal venous insufficiency. J Vasc Surg 2009;50:1348-1358.
15. Khan O, Filippi M, Freedman MS, et al. Chronic cerebro-spinal venous insufficiency and multiple sclerosis. Ann Neurol 2010;67:286-290.
16. Poloni GU, Zamboni P, Haacke EM, et al. Quantitative venous vasculature assessment on susceptibility-weighted imaging reflects presence of severe chronic venous insufficiency in the brain parenchyma of multiple sclerosis patients: a case-control study. Neurology 2010;74(suppl 2):A288.
17. Sundstrom P, Wahlin A, Ambarki K, Birgander R, Eklund A, Malm J. Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. Ann Neurol 2010;68:255-259.
18. Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010;68:173-183.
19. Kuenz BDF, Berger T, Reindl M. Diagnostic biomarkers in multiple sclerosis. Expert Opin Med Diagn 2007;1:225-233.
20. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A mul-tifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008;255:1023-1031.
21. Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010;219:1-7.
22. Ottervald J, Franzen B, Nilsson K, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomar-kers. J Proteomics 2010;73:1117-1132.
23. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009;73:32-38.
24. Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010;31:770-788.
25. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817.
26. Ranjeva JP, Audoin B, Au Duong MV, et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol 2005;26:119-127.
27. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-412.
28. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-1127.
29. Cohen JA, Barkhof F, Comi G, et al, Group TS. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
30. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
31. Giovannoni G, Comi G, Cook S, et al, CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-426.
32. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007;68:985-990.
33. Major EO. Reemergence of PML in natalizumab-treated patients: new cases, same concerns. N Engl J Med 2009; 361:1041-1043.
34. Rudick R, Polman C, Goodman A, et al. Effects of natali-zumab treatment on the presence of JC virus DNA in blood or urine in multiple sclerosis patients. Neurology 2010;74(suppl 2):A390.
35. Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010;16:503-510.